Provided By GlobeNewswire
Last update: Apr 18, 2024
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO, the “Company” or “Histogen”), a drug development company for treatment of bacterial skin infections, today announced that it has filed voluntary petitions for relief under subchapter V of Chapter 11 of the U.S. Bankruptcy Code (“Chapter 11”) in the United States Bankruptcy Court for the Southern District of California to confirm a plan of liquidation that will distribute all value to stakeholders, including shareholders.
Read more at globenewswire.com